A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Group sequential methods allow clinical trials to perform pre-planned interim analyses with the option to stop early for efficacy, futility, or safety — without inflating the overall Type I error rate. The fundamental problem is that each interim look at the data constitutes a statistical test, and multiple tests inflate the probability of a false positive (a trial with 5 equally-spaced interim analyses at alpha = 0.05 each would have an overall alpha of approximately 0.14). Group sequential boundaries (O'Brien-Fleming, Pocock, alpha-spending functions) distribute the overall alpha across the interim analyses, using more conservative thresholds at early looks and progressively relaxing them. This allows ethical early stopping when evidence of benefit or harm is overwhelming, while preserving the statistical integrity of the final analysis.
Clinical trials can last years and enroll thousands of patients. Ethical and practical considerations demand the ability to examine accumulating data periodically: if the treatment is overwhelmingly effective, withholding it from the control group becomes unethical. If it is harmful, continuing enrollment is indefensible. If it is clearly futile, further enrollment wastes resources and exposes patients to unnecessary risk. But looking at the data repeatedly creates a statistical problem: each look is an opportunity for a false positive.
The mathematics are straightforward. If you test at alpha = 0.05 at each of k independent analyses, the probability of at least one false positive is 1 - (0.95)k. With 5 analyses, this is approximately 23%. Group sequential methods solve this by spending the total alpha budget across the analyses. Pocock boundaries spend alpha equally at each look, requiring a more stringent threshold at each analysis (approximately alpha/k at each look for k looks). O'Brien-Fleming boundaries spend very little alpha early and concentrate it at the end, requiring overwhelming evidence for early stopping but preserving nearly the full alpha for the final analysis.
The alpha-spending function approach (Lan and DeMets, 1983) generalizes this framework by defining alpha expenditure as a continuous function of the information fraction — the proportion of total planned information (events, patients) accumulated at each look. This allows the timing and number of interim analyses to be flexible — they need not be equally spaced or even pre-specified in number. The spending function determines how much of the total alpha has been consumed at each information fraction, and the boundary is computed accordingly. The O'Brien-Fleming and Pocock spending functions reproduce the corresponding fixed boundaries when analyses are equally spaced.
Futility boundaries complement efficacy boundaries by allowing early stopping when the treatment is unlikely to show benefit even with the full sample. Conditional power — the probability of achieving statistical significance at the final analysis, given the interim data — is the standard metric. If conditional power falls below a threshold (e.g., 10-20%), the treatment is unlikely to succeed and further enrollment is questionable. Unlike efficacy boundaries, futility boundaries do not inflate the Type I error rate (they stop the trial before it can reject the null). However, they do affect power (stopping a trial that might have succeeded with more data), so the cutoff must balance statistical consequences against ethical obligations. Data Safety Monitoring Boards (DSMBs) review interim results in the context of these boundaries but retain clinical judgment to deviate when the overall evidence landscape warrants it.